Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| ASCENDIS PHARMA | 2 | - | -3,03 % | ||
| REGENERON PHARMACEUTICALS | 1 | 22 | 0,00 % | ||
| EXELIXIS | 1 | 8 | -0,11 % | ||
| HARROW | 1 | 4 | +0,44 % | ||
| MANNKIND | 1 | 2 | +1,77 % | ||
| WAVE LIFE SCIENCES | 1 | 2 | -1,69 % | ||
| ERASCA | 1 | 2 | +0,59 % | ||
| PROTHENA | 1 | 1 | 0,00 % | ||
| OCULAR THERAPEUTIX | 1 | 1 | -1,66 % | ||
| COGENT BIOSCIENCES | 1 | - | -1,55 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Erasca, Inc. (ERAS): A Bull Case Theory | 2 | Insider Monkey | ||
| Sa | MannKind Corporation (MNKD): A Bull Case Theory | 4 | Insider Monkey | ||
| Sa | Wave Life Sciences Ltd. (WVE): A Bull Case Theory | 2 | Insider Monkey | ||
| Sa | Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory | 6 | Insider Monkey | ||
| Sa | Harrow, Inc. (HROW): A Bull Case Theory | 2 | Insider Monkey | ||
| Sa | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Sa | Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)? | 2 | Insider Monkey | ||
| Sa | 3 Reasons Exelixis Stock Could Deliver Market-Beating Returns Over the Next Decade | 5 | The Motley Fool | ||
| Sa | Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq? | 7 | Barchart.com | ||
| Sa | FDA Grants Accelerated Approval To Ascendis Pharma's YUVIWEL For Achondroplasia In Children | 10 | RTTNews | ||
| Sa | Aardvark Therapeutics Pauses Phase 3 Trial Of ARD-101 In Prader-Willi Syndrome; Stock Plunges | 10 | RTTNews | ||
| Sa | Prothena To Buy Back Up To $100 Mln Of Shares | 4 | RTTNews | ||
| Sa | Ascendis Pharma wins FDA approval for navepegritide for achondroplasia | 1 | Seeking Alpha | ||
| Sa | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | 411 | AFX News | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| Sa | Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange | 6 | Investing.com | ||
| Sa | BioMarin Pharmaceutical Inc.: U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) | 923 | PR Newswire | Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study
PALYNZIQ is the... ► Artikel lesen | |
| Sa | Ascendis Pharma: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older | 294 | GlobeNewswire (Europe) | The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric... ► Artikel lesen | |
| Fr | Harrow Health Q4 2025 Earnings Preview | 3 | Seeking Alpha | ||
| Fr | Disc Medicine undergoes restructuring plan; slashes 20% of workforce | 4 | Seeking Alpha | ||
| Fr | Tectonic Therapeutic, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.